Retrospective claims analysis of best supportive care costs and survival in a US metastatic renal cell population

INTRODUCTION: Survival and best supportive care (BSC) costs for patients with metastatic renal cell carcinoma (mRCC), after stopping therapy, are poorly characterized yet an important aspect of patient care. This study examined survival and costs associated with BSC after one or two lines of therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Henk, Henry J, Chen, Connie, Benedict, Agnes, Sullivan, Jane, Teitelbaum, April
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3711649/
https://www.ncbi.nlm.nih.gov/pubmed/23874112
http://dx.doi.org/10.2147/CEOR.S45756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3711649/
https://www.ncbi.nlm.nih.gov/pubmed/23874112
http://dx.doi.org/10.2147/CEOR.S45756

Ejemplares similares